
    
      The study will consist of a Screening phase within 28 days prior to cycle 1 day 1. Subjects
      once enrolled will enter the Treatment phase, in which patients will be treated until
      progression, or study discontinuation due to other reasons. Subjects will enter the long term
      Follow-up phase of the study where data will be collected every 3 months for up to 5 years on
      Secondary primary malignancies, survival, subsequent anti myeloma treatments and date of
      progression. Subjects will be recruited into one of 3 cohorts depending on the severity of
      their renal impairment.
    
  